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this complicates further response assessment since the return of steady state IgM levels may take 5-6 weeks. 13 Moreover, in many patients with WM, ongoing plasmapheresis might be required. As such, novel biomarkers are needed to more accurately assess disease burden in WM patients undergoing rituximab-based therapy, as well as plasmapheresis.
Soluble CD27 (sCD27) is a tumor necrosis factor (TNF) family member, which is secreted by WM cells. In previous studies, we demonstrated that sCD27 could induce the expression of CD40 ligand and A proliferation-inducing ligand (APRIL) on bone marrow mast cells, and through which the growth and survival of WM cells could be supported. 14 Moreover, in this study, sCD27 levels were serially measured in patients whose clinical outcomes (responder, stable disease, or progressive disease) were known, and were found to be highly correlated with serial changes in serum IgM levels in all outcome categories. In as well, sCD27 correlated with the International Prognostic Staging System-untreated WM patients. 15 We therefore performed this study to assess the value of sCD27 as a response marker in patients whose outcomes to therapy were known, and in whom a rituximab-mediated IgM flare was observed, as well as in patients with WM undergoing plasmapheresis.
Patients and Methods

Patient Characteristics
We identified 8 patients with WM who experienced a clinically documented rituximab-mediated IgM flare, for whom serial IgM levels and stored serum samples for sCD27 testing were available. The median age for these patients was 68 years (range, 62-79 years) and the median number of previous therapies was 0 (range, 0-4 therapies). Three of the patients were previously treated, and one of these patients had previously received rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP). Therapy leading to the IgM flare consisted of rituximab monotherapy (n = 1), cyclophosphamide/prednisone/rituximab (n = 2), thalidomide/rituximab (n = 4), and lenalidomide/ rituximab (n = 2). Seven of these patients achieved a response (1 near complete, 3 partial, 3 minor), and one patient achieved stable disease following therapy. Response assessments were based on consensus criteria using serial changes in serum IgM levels. 16 The median baseline IgM was 3515 (range, 1900-3890 mg/dL), and the median BM involvement was 30% (range, 5%-80%). We also identified 3 patients with WM who had undergone plasmapheresis for whom serial IgM levels were available, and stored serum samples for sCD27 were also available. The median age for these patients was 69 years (range, 59-73 years), median baseline serum IgM was 6940 mg/dL (range, 6380-12,300 mg/dL), and median BM involvement was 30% (range, 5%-40%). All 3 patients were treatment naive before plasmapheresis.
ELISA Analysis of WM Patient Serum
All patients provided informed written consent, and the institutional review board approved this study. Serum samples obtained before and after treatment from patients were utilized for these studies. Samples were aliquoted and stored at -80°C, and subsequently quick thawed in a warm bath for determination of sCD27 levels. Previous studies in our laboratory had demonstrated no significant effect of freezing on determination of sCD27 levels (data not shown). To evaluate for sCD27 levels, 100 µL of patient was analyzed by an ELISA kit per manufacturer's instructions (Bender Medsystems, Burlingame CA).
Statistical Analysis
Comparison of pre-and post-treatment parameters was performed using a 2-tailed students t test on Microsoft Excel™ software. A P value ≤ 0.05 was deemed to be significant for the above studies. Table 2 Abbreviations: BM = bone marrow; PP = plasmapheresis; sCD27 = soluble CD27; sIgM = serum Igm; WM = Waldenström's macroglobulinemia
Results
Serum IgM and sCD27 Levels Following Rituximab-Induced IgM Flare
Among the 8 patients who experienced a rituximab-mediated IgM flare, IgM levels rose from 3515 to a peak of 5270 mg/dL (P = .008). The median time to peak IgM levels post-rituximab treatment for these patients was 51 days (range, 14-177 days). At baseline, the median sCD27 level was 174.1 U/mL, coinciding with the observed baseline serum IgM levels for these 8 patients.
Following rituximab treatment and coinciding with peak serum IgM levels, median sCD27 levels declined to 155.9 U/mL (P = .012), with a decline observed in all patients (Table 1) . In 3 patients, BM biopsies were performed post rituximab treatment which confirmed the presence of an IgM flare, as well as reduction in disease burden predicted by measurement of sCD27 levels ( Table 1) .
Serum IgM and sCD27 Levels Following Plasmapheresis
Among 3 patients undergoing plasmapheresis, IgM levels declined from 6940 to 4770 mg/dL (P = .031) at a median of 2 days (range, 2-29 days). At baseline, the median sCD27 level was 116.9 U/mL, coinciding with the observed baseline serum IgM levels for these 3 patients. Following plasmapheresis, and coinciding with the obtained post-plasmapheresis serum IgM levels (Table 2) , no significant change in sCD27 levels occurred (123.9 U/mL; P = .317).
Discussion
The assessment of disease burden is often difficult in patients with WM who receive rituximab due to the induction of an IgM flare, and following the removal of serum IgM by plasmapheresis. In such circumstances, serial BM biopsies have been utilized to clarify a patient's underlying disease burden, adding to patient discomfort, delay in response assessment, as well as treatment costs. We therefore evaluated sCD27 as a marker of disease burden in WM patients experiencing a rituximab-related IgM flare, as well as undergoing plasmapheresis. sCD27 is a TNF family member secreted by WM cells through proteolytic cleavage, which we previously showed correlated strongly with disease progression and response. The results of the present study demonstrate that sCD27 is a faithful marker of disease burden in patients experiencing a rituximab-related IgM flare, and correctly predicted response outcome. In as well, sCD27 levels remained unaffected by plasmapheresis in WM patients. The results of this study support the broader investigation of sCD27 as an adjunct in the clinical management of patients undergoing treatment with rituximab and/or plasmapheresis. Further validation of the use of sCD27 in other WM disease related circumstances where IgM levels are potentially unreliable such as cryoglobulinemia, or bortezomibrelated paraprotein suppression might lead to additional roles for the use of sCD27 in the management of patients with WM.
